Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$57.22
-0.1%		$52.05
$25.36
▼
$61.70
$2.91B1.24876,634 shs317,879 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$166.91
-0.6%		$172.76
$73.16
▼
$191.62
$9.83B0.69867,516 shs214,739 shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$78.34
+2.7%		$78.82
$58.32
▼
$101.40
$10.50B0.961.48 million shs526,657 shs
Insulet Corporation stock logo
PODD
Insulet
$138.72
+3.6%		$140.57
$126.40
▼
$354.88
$9.61B1.111.39 million shs365,290 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+0.76%+7.48%+2.71%+60.86%+61.91%
Glaukos Corporation stock logo
GKOS
Glaukos
+1.39%-2.66%-1.89%+7.90%+96.60%
Globus Medical, Inc. stock logo
GMED
Globus Medical
+0.12%+3.25%+0.80%-5.25%+31.48%
Insulet Corporation stock logo
PODD
Insulet
-3.04%-0.32%-2.81%-18.55%-57.92%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$57.22
-0.1%		$52.05
$25.36
▼
$61.70
$2.91B1.24876,634 shs317,879 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$166.91
-0.6%		$172.76
$73.16
▼
$191.62
$9.83B0.69867,516 shs214,739 shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$78.34
+2.7%		$78.82
$58.32
▼
$101.40
$10.50B0.961.48 million shs526,657 shs
Insulet Corporation stock logo
PODD
Insulet
$138.72
+3.6%		$140.57
$126.40
▼
$354.88
$9.61B1.111.39 million shs365,290 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+0.76%+7.48%+2.71%+60.86%+61.91%
Glaukos Corporation stock logo
GKOS
Glaukos
+1.39%-2.66%-1.89%+7.90%+96.60%
Globus Medical, Inc. stock logo
GMED
Globus Medical
+0.12%+3.25%+0.80%-5.25%+31.48%
Insulet Corporation stock logo
PODD
Insulet
-3.04%-0.32%-2.81%-18.55%-57.92%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
2.58
Moderate Buy$54.10-6.59% Downside
Glaukos Corporation stock logo
GKOS
Glaukos
2.80
Moderate Buy$181.437.78% Upside
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.88
Moderate Buy$99.4626.60% Upside
Insulet Corporation stock logo
PODD
Insulet
2.46
Hold$186.6835.52% Upside

Current Analyst Ratings Breakdown

Latest ATRC, GMED, GKOS, and PODD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$190.00
10/12/2026
Insulet Corporation stock logo
PODD
Insulet
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$275.00 ➝ $190.00
10/12/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$55.00 ➝ $63.00
10/12/2026
Glaukos Corporation stock logo
GKOS
Glaukos
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$202.00 ➝ $205.00
10/9/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingHold (C+)
10/8/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C-) ➝ Hold (C)
10/7/2026
Insulet Corporation stock logo
PODD
Insulet
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
10/6/2026
Insulet Corporation stock logo
PODD
Insulet
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageUnderweight ➝ Equal Weight$150.00
10/2/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Freedom Capital logo
Freedom Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
10/1/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$115.00 ➝ $85.00
9/22/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$190.00 ➝ $210.00
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$534.53M5.51$0.32 per share181.70$9.89 per share5.86
Glaukos Corporation stock logo
GKOS
Glaukos
$507.44M19.57N/AN/A$11.42 per share14.74
Globus Medical, Inc. stock logo
GMED
Globus Medical
$3.14B3.35$6.47 per share12.15$33.86 per share2.32
Insulet Corporation stock logo
PODD
Insulet
$3.05B3.13$6.30 per share21.85$21.54 per share6.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$11.45M$0.21276.44128.70N/A1.85%2.34%1.77%11/3/2026 (Confirmed)
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.25N/A306.06N/A-30.68%-6.37%-4.78%10/28/2026 (Confirmed)
Globus Medical, Inc. stock logo
GMED
Globus Medical
$537.87M$3.9120.0314.581.2317.02%14.57%12.62%11/5/2026 (Estimated)
Insulet Corporation stock logo
PODD
Insulet
$247.10M$5.3525.7417.871.0912.29%29.29%13.31%11/4/2026 (Confirmed)

Latest ATRC, GMED, GKOS, and PODD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.20N/AN/AN/A$792.28 millionN/A
11/4/2026Q3 2026
Insulet Corporation stock logo
PODD
Insulet
$1.59N/AN/AN/A$832.71 millionN/A
11/3/2026Q3 2026
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.0427N/AN/AN/A$151.15 millionN/A
10/28/2026Q3 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.0955N/AN/AN/A$168.03 millionN/A
8/6/2026Q2 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.10$1.34+$0.24$1.10$782.88 million$789.61 million
8/5/2026Q2 2026
Insulet Corporation stock logo
PODD
Insulet
$1.47$1.66+$0.19$1.37$787.39 million$801.70 million
7/29/2026Q2 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.2105-$0.14+$0.0705-$0.31$150.93 million$185.61 million
7/23/2026Q2 2026
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.0017$0.18+$0.1817$0.18$151.80 million$153.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.14
4.22
3.19
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.04
4.46
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.62
2.93
Insulet Corporation stock logo
PODD
Insulet
0.65
2.48
1.83

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Insulet Corporation stock logo
PODD
Insulet
N/A

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
4.00%
Glaukos Corporation stock logo
GKOS
Glaukos
5.90%
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.38%
Insulet Corporation stock logo
PODD
Insulet
0.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,35050.87 million48.83 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.98 million55.50 millionOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
6,000134.26 million109.59 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
5,40069.35 million69.10 millionOptionable

Recent News About These Companies

Insulet (PODD) Gets a Hold from Leerink Partners
October 14 at 7:39 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PODD/pressreleases/6702041/insulet-podd-gets-a-hold-from-leerink-partners/
Insulet (NASDAQ:PODD) Stock Sale Reported by Rep. Gilbert Ray Cisneros, Jr.
October 14 at 2:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-insulet-nasdaq-podd-stock-sale-reported-by-rep-gilbert-ray-cisneros-jr-2026-10-14/
Insulet’s Omnipod Discover data platform begins full US rollout
October 13 at 10:52 PM  |  massdevice.comhttps://www.massdevice.com/insulets-omnipod-discover-data-platform-begins-full-us-rollout/
Insulet Announces Omnipod Discover Now Available in U.S.
October 12 at 8:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261012734213/en/Insulet-Announces-Omnipod-Discover-Now-Available-in-U.S./
Insulet (NASDAQ:PODD) Raised to Buy at Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104368
Insulet (NASDAQ:PODD) Stock Bumped Up to "Buy" by Wall Street Zen
October 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-insulet-nasdaq-podd-stock-bumped-up-to-buy-by-wall-street-zen-2026-10-10/
Barclays initiates coverage of Insulet with equal-weight rating
October 8, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/barclays-initiates-coverage-of-insulet-with-equal-weight-rating/ar-AA2dLKk9
Insulet (NASDAQ:PODD) Stock Moved Up to Hold by Barclays
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099322
Insulet (NASDAQ:PODD) Upgraded to Hold at Barclays
October 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-insulet-nasdaq-podd-upgraded-to-hold-at-barclays-2026-10-08/
Analysts Offer Insights on NA Companies: Insulet (PODD) and General Motors (GM)
October 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PODD/pressreleases/4900484/analysts-offer-insights-on-na-companies-insulet-podd-and-general-motors-gm/
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/insulet-announce-third-quarter-2026-110000772.html
Insulet Corporation (NASDAQ:PODD) Stock Has Consensus Target Price of $195.40
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-insulet-corporation-nasdaq-podd-stock-has-consensus-target-price-of-19540-2026-09-30/
Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/insulet-sees-emerging-headwinds-market-153342394.html
Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/insulet-sees-emerging-headwinds-market-153342394.html
Insulet (PODD) Stock May Trade At A Discount To Fair Value
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/insulet-podd-stock-may-trade-051043414.html
Insulet (PODD) Reworked Its Debt, Is The Stock Still Cheap?
September 25, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/insulet-podd-reworked-debt-stock-111220704.html
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
September 25, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995879/why-insulet-podd-is-a-top-growth-stock-for-the-long-term?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_growth_score-2995879
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-insulet-targets-type-2-retention-as-omnipod-6-and-global-growth-gain-momentum-2026-09-25/
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
September 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949558-insulet-corporation-podd-presents-at-bernstein-insights-healthcare-leaders-and-disruptors-3rd
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
September 24, 2026  |  barchart.comhttps://www.barchart.com/story/news/4771377/how-is-insulet-s-stock-performance-compared-to-other-medical-devices-stocks
Insulet stock heads into the open after a flat Nasdaq close
September 22, 2026  |  ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

AtriCure stock logo

AtriCure NASDAQ:ATRC

$57.22 -0.08 (-0.14%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Glaukos stock logo

Glaukos NYSE:GKOS

$166.91 -0.98 (-0.59%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Globus Medical stock logo

Globus Medical NYSE:GMED

$78.34 +2.03 (+2.66%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Insulet stock logo

Insulet NASDAQ:PODD

$138.72 +4.79 (+3.57%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas